Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase 3 study A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Dimopoulos, M A, Stewart, A K, Masszi, T, Špička, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, G G, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Ro, S, Aggarwal, S, Moreau, P, Palumbo, A
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436074/
https://ncbi.nlm.nih.gov/pubmed/28430175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.31
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados